Bio B2B 〉 Selective Search Results
Your Selection Setting ：Co-development；
Selective Search Results :
Pipeline & Platform 62 record(s)；
•iStat's technology platform, Methylation-Specific-PCR (MSP), is a proprietary DNA-based technology that detects tumor-specific gene methylation with high precision and accuracy.•Aberrant DNA methylation has known to be associated with human cancers through epigenetic gene silencing of tumor suppressor and DNA repair genes. iStat's MSP provides optimal solutions for physicians in cancer diagnosis
Patented CMx® Platform
Circulating Tumor Cells as Biomarker for Early Cancer Detection. Saving Life, It's in Our Blood.The CMx® Platform uses a biomimetic, lipid-bilayer coated microﬂuidic chip to capture these rare cells in peripheral blood. For colonrectal cancer, the test can be useful in cases of non-compliance with recommended colonoscopies or messy stool tests, and as a supplemental screening.
EG12014 Trastuzumab Biosimilar
Eirgenix aims to commercialize the first biosimilar product manufactured in Taiwan for the global market.Indication: HER2 Breast CancerExpected Product Launch: 2020Status: Phase 1 completed, BE established between EG12014 / EU & US HerceptinAdvantages of EG12014- The development of EG12014 follows EMA/FDA published guidance and past experience- EirGenix clinical study set up is considered an asset
INNOPHARMAX has extensive pharmaceutical R&D experience, with former researchers who worked for the Medical and Pharmaceutical Industry Technology and Development Center in Taiwan (which is the most influential pharmaceutical technology developing organization funded by the Taiwan government), INNOPHARMAX's R&D team has been highly praised by numerous pharmaceutical
low-alcohol formulation (iLEF) platform
Intech Biopharm focus on new dosage, new combination, new delivery and high barrier generic drug development and manufacturing for respiratory therapy area. We are currently one of the leading companies, and the only one in Taiwan, that can provide and manufacture high barrier obstructive airway diseases drug and our competitive advantage are as follow: iLEF platform: It has a low-alcohol
Synthetic lethality (SL) is a concept in which cell death is induced by the combination of two non-lethal mutations, while mutation alone is not sufficient to affect cell survival. Recently, SL has been proposed as a novel anticancer strategy that is promising to be highly selective. If a cancer-specific mutation combined with a drug-induced mutation have SL interactions, it will selectively
Homogeneous antibody drugs (CHO-H01, H02, H03)
A unique glycan structure was identified for monoclonal antibodies with improved activity. With the proprietary technology developed by CHO Pharma, the Fc-glycan structure of therapeutic antibodies can be engineered to a homogeneous glycoform, which displayed enhancement of antibody-dependent cell-mediated cytotoxicity (ADCC), in vivo anti-tumor activities, and potential anti-inflammatory properties
Small Molecule Drugs
ScinoPharm possesses a full range of chemistry capabilities and has extensive experience in synthesizing complex molecules. Depending on individual requirements, we develop new synthetic routes, or scale up and optimize processes based on the customer's technology. Our synthesis studies include structured Design of Experiment. (DoE) methods used to identify optimal conditions, factors that most
TABP's transcriptional factor protein drugs are developed based on the fact that transcription factors can specifically act on the promoter of a gene. Comparable to monoclonal antibodies' specificity, the TABP's protein drugs can target to and regulate individual gene whose function people wish to change and by this means we can determined the proliferation and differentiation fate of cells. Advanced
CVM-1118 is a small molecule NCE (new chemical entity). It has high anti-cancer activity, good safety margin, and multiple mechanisms of action targeting cancer, especially its unique ability to inhibit vasculogenic mimicry (VM). CVM-1118 is currently being developed into a next generation oral anti-cancer drug. CVM-1118 has great potential showing inhibitory effect towards breast, ovarian, colon,
TLC599 is our proprietary BioSeizer formulation of dexamethasone sodium phosphate (DSP) designed to provide sustained pain management over an extended period of three months or more. TLC599 has the potential to enable patients to receive both immediate and sustained benefit from the local delivery of a highly potent and clinically validated steroid that typically has a very short half-life. Our
Six Genomic Technology Platforms
IVD Sequencing & NGS analysisSNP genotyping analysisGene Chip analysisFunctional genomics analysisClinical genomics analysisBioinformatics analysis
Core Technology: Pegylation PlatformIn the field of protein drug design, the process of pegylation of the therapeutic protein preserves its biological activity by targeting the PEG polymer (polyethylene glycol) at a specific and defined region on the protein. PharmaEssentia's pegylation technology platform is designed to increase the protein drug's efficacy by prolonging its circulation in
SB05 is an innovative composition of the established cytostatic drug paclitaxel combined with neutral and positive lipids. Due to the positively charged lipids, SB05 interacts with newly developing, negatively charged endothelial cells, which are especially required for the growth of tumor blood vessels. The SB05 paclitaxel component attacks the activated endothelial cells as they divide, thus targeting
Tmax of the current extended release tablets is too long, so children lose attention in learning when they start classes in the early morning.With both advantages of immediate and extended release, the unique multi-stages hot melt capsule releasing technology is able to become effective in early stage and sustainably release the drug to maintain the efficacy.The patented Oradur® formulation
The PixoTest® technology utilizes the lighting and image sensing module of the smartphone (or mobile device) to detect the color change reaction on the biochemical test strip (US patent granted). The image of the test strip is captured by the front camera of the smartphone and analyzed via the measurement algorithm to turn out a quantified or semi-quantified result. With the control on light
TiMAX Dental Service
In order to provide the most reliable and complete medical quality and service, TiMAX will also introduce the concept of brand service and incorporate advanced technology and dental products to the public.Through the innovative concept of an open surgery center structure and the technology of dental implants system, TiMAX Dental Service also makes use of Taiwan's excellent ICT industry technology
PHN131 (Treat moderate to severe pain)
Advantages of the productNew oral formulation derived from an approved analgesic injectable - NalbuphinePatented technology inhibits first-pass metabolism to improve oral bioavailabilityPotency equivalent to Morphine per milligram basisLow physical dependence and addictionConvenience with oral administrationCeiling effect for side-effect of respiratory depressionNotable achievementsCo-development with
FB825 is a humanized monoclonal antibody that binds to the CεmX domain, leading to death of the membrane IgE+ B lymphocytes by inducing apoptosis and antibody-dependent cellular cytotoxicity (ADCC) in a dosing-dependent manner. FB825 can stand alone as a monotherapy or in combination with Xolair for the treatment of allergic asthma and IgE-mediated diseases.
Physio-Chemical LaboratoryChemistry faculty of RRL conducts wide range of tests to evaluate the Physical-chemical properties of pure and formulated Agrochemicals in compliance with EEC, OECD, OPPTS and SANCO guidelines.We follow internationally accepted methods like FAO, WHO, AOAC and CIPAC with strict compliance to OECD principles of Good Laboratory Practices.The areas of expertise include:5
TAH9901 ADHD Trandermal Patch
TAH9901 comprise of a ADHD treatment proven to be safe and efficacious for over 50 years, and as a stimulant, is a first line therapy for children with ADHD. TAH 9901 offers a transdermal once daily treatment for ADHD.Uniqueness:• Reducing dosing frequency due to longer duration• Improved bioavailability• Uniform plasma levels, resulting in reduced side effect• Possibility of terminating
CellMax SMSEQ® PlatformAnalytical specificity of ≥99.999%CellMax Life's liquid biopsy blood test uses next generation sequencing technology to detect gene alterations.The patented technology, combined with years of research and development advancements enables CellMax to offer an extremely cost effective and liquid biopsy, profiling 73 genes from circulating tumor DNA (ctDNA), to identify
Furaprevir is a novel inhibitor of Hepatitis C virus (HCV) NS3/4A protease. This protease is essential for HCV replication and inhibitors have been shown to be effective in reducing viral load. TaiGen's goal is to develop a highly effective and affordable combination regimen with TG-2349 as the anchor.TG-2349 possesses the following unique characteristics that differentiate it from the competitors:Active
CX-5461: RNA Polymerase I (Pol I) Inhibitor Program
The p53 protein normally functions as a tumor suppressor by causing cancer cells to self-destruct. Activating p53 to kill cancer cells is a well validated anticancer strategy and many approaches are being employed to exploit this pathway. By targeting RNA Polymerase I (Pol I) to activate p53 in cancer cells but not normal cells, through the nucleolar stress pathway, Senhwa's first-in-class
TLC399 is our proprietary BioSeizer formulation of dexamethasone sodium phosphate (DSP) intended as an intravitreal, or in-eye, injection for the treatment of macular edema due to retinal vein occlusion. TLC399 in preclinical models has been shown to provide therapeutic levels of DSP in the eye for at least six months after a single administration. A Phase I/II safety trial has demonstrated encouraging
New combination for treating Sialorrhea
• Combination of two compounds with different Mechnism of Action to reduce the secreting of saliva.• First oral treatment for sialorrhoea of Parkinson's Disease.• Results of Phase IIa study, published in the 17th International Congress of Parkinson's Disease and Movement Disorders, shows efficacy and safety.
SB04 is a conventional drug in new use to treat patients with dry AMD. SB04 has many different mechanisms to treat patients without invasive way; even patient self-applied medication. Eye drop formulation505(b)(2) regulatory pathwayFast Track Pathway for IND in Phase II/IIIPhase II/III clinical trial is ongoing in the US and Taiwan.
Rexis® is being developed as an add-on injection therapy for patients with sepsis. Several studies have demonstrated a reduction in mortality rate with the addition of Rexis® compared to the standard treatment. Rexis® will soon initiate pivotal clinical trials follow by regulatory registrations in 2016. We hope to increase the survival rate of sepsis and bring hope to patients
Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)
CHO-A04 is a humanized monoclonal antibody targeting a novel carbohydrate antigen specifically and highly expressed on more than 10 cancer types, including triple negative breast cancer (TNBC) and pancreatic cancer. CHO-A04 kills cancer cells via antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). The proof-of-concept (POC) study for CHO-A04 has been well
PHN014 (Acute ischemia stroke)
Advantages of the productPHN014 is extracted, isolated and refined with high purity from the Astragalus membranaceus (黃耆) , which has been described in the classical texts as a qi-supplementing medicine.Long-term human experience show no drug- related toxicityPHN014 meet the current trend of new drug development ,with two-way immune regulationIt's very safe and without the risk for inducing the
FB825 (Anti-CεmX;h4B12) was developed by the same inventor who developed anti-IgE therapeutics. FB825 is a humanized monoclonal antibody that targets to the the CεmX domain and kills the membrane IgE+ B lymphocytes by ways of apoptosis and antibody-dependent cellular cytotoxicity (ADCC).By targeting to mIgE+B lymphocytes, FB825 has a long-lasting effect in down-regulating
CX-4945: CK2 Inhibitor Program
CK2 (Casein kinase 2) is a protein kinase that has elevated activity in many cancers and has a direct role in DNA damage repair. The DNA repair pathways enable tumor cells to survive damage induced by treatment with chemotherapeutic agents. Inhibitors of DNA repair pathways have been shown to increase the efficacy of DNA-damaging chemotherapeutic drugs when these are used in combination
Injectable Manufacturing Services
Already the leader in providing oncological APIs to regulated markets worldwide, ScinoPharm is poised to extend the service to offer finished dosage form of injectable products. With the completion of injectable plant in Tainan campus in Taiwan and combining the API capability, ScinoPharm is able to provide integrated solutions for one-stop shopping of injectable products in a flexible, reliable and
Burixafor( TG-3000) , is a novel, potent and selective chemokine receptor antagonist discovered by TaiGen. Burixafor rapidly mobilizes stem cells and progenitor cells from the bone marrow into peripheral circulation. Burixafor has completed Phase 2 study in autologous stem cell transplantation in the US. Another Phase 1 study in chemosensitization has also completed in China by 2018. Other potential
Poor solubility and high toxicity are significant problems with many new promising therapeutic approaches in oncology. By using TLC's lipid-based technology to improve solubility characteristics of a new derivative from a well-known chemotherapeutic drug (camptothecin), we were able to enhance its clinical development potential. In addition, TLC388 shows
SB01 is a new drug originated in Taiwan, from discovery, research and development, preclinical ADME, API and finished product manufactured to the USFDA IND. SB01 is an injectable anti-cancer NCE with multiple anti-tumor MOATreatement of cholangiocarcinoma has FDA Orphan Drug Designation clearancePhase I results show a favorable safety profilePhase II clinical trial of SB01 has
Isoniazid without liver toxicity
1. The common Tuberculosis (TB) drug Isoniazid has the most side effect of hepatotoxicity among all drugs, which is considered to be the major barrier of TB treatment.2. Isoniazid with new formulation has no hepatotoxicity due to the special excipient.
Dual-targeted bifunctional anti-flu drug (CHO-S05)
A novel series of dual-targeted bifunctional anti-flu drugs comprising of influenza virus inhibition and pro-inflammatory cytokine suppression are designed, synthesized and evaluated. In vitro and in vivo functional analyses have shown remarkable protection of cells and mice by oral administration against H1N1 & H5N1 influenza viruses.
PHN031 (Osteoporosis prevention)
Advantages of the productSelection of native plants for control the medicinal origin and qualityLong-term human experience show no drug- related toxicityThere are dual affects in enhancing bone formation index and restraining bone loss indexCharacteristic fingerprint to ensure superior quality controlWell-defined specifications to prove the consistency of quality among batches
MS-20 is a mixture of soy fermentation metabolites which is produced in strictly controlled fermenter and with carefully chosen microorganisms that mimics human intestinal environment.The manufacturing and R&D procedures of Chemo Young follow the international regulations.MS-20 was approved as new drug by TFDA in 2011.MS-20 acts as an immunemodulator and probiotics to improve immunity and
FB704A is a fully human monoclonal antibody against human Interleukin-6 (IL6) and developed by Fountain's proprietary fully-human antibody library and affinity maturation technology.IL6 is a multifunctional cytokine that regulates pleiotropic roles in immune system, inflammation and hematopoiesis. Therapeutic targeting on the IL6 is therefore considered to be a potential treatment strategy for
TLC's own formulation of liposome encapsulated doxorubicin effectively reduces the side effects of doxorubicin and broadens its indications.
ScinoPharm provides comprehensive peptide synthesis technologies with full analytical and regulatory support. With rich knowledge and expertise in peptide synthesis and proprietary platform technologies, ScinoPharm can design and develop higher yield processes for larger-scale peptides that are scalable and more cost effective, ensuring faster time-to-market.Peptide Synthesis CapabilitiesSynthesis
Multiple-Phasic Release Technology (MPRT)
Through Orient Pharma's patented technology, incompatible ingredients or drugs with different release profiles can be enclosed in a single capsule or tablet for the development of new drugs.
Glycan arrays and glycoprobes
Synthetic oligosaccharides and/or polysaccharides are immobilized on a solid supported in a spatially-defined arrangement to mimic the glycan expression on cell surface. The arrays of various glycans can be used for the diagnosis and prognosis of the disease such as cancer and infectious disease. They can also be used as research tools such as the validation of glycan binding protein and antibody,
FB317, a biosimilar of omalizumab, inhibits the binding of IgE to the FcεRI on the surface of mast cells and basophils by neutralizing free IgE in the blood. Reduction of surface bound IgE on FcεRI-bearing cells decreases the release of mediators and prevents allergic responses.Mostly on the clinical treatment with antihistamines, sympathomimetic drugs, corticosteroids and
TRIA11 is a biosimilar indicated for osteoporosis. The current global sales of the original product reaches to $1.7 billion. An injection pen is also developed to enhance the convenience of use. TRIA11 is planned to launch in EU first, and TSH Biopharm has consulted EMA for the development plan. TRIA11 is expected to move into clinical stage by the end of 2019.
TLC178 is a formulation of vinorelbine loaded into liposomes, designed to reduce toxicity and improve efficacy with fewer administrations.We are initially developing TLC178 for pediatric RMS. The increased specificity of TLC178 for tumor versus non tumor tissue through the use of our NanoX technology, which utilizes enhanced permeability and retention effects, will enable greater dose intensity
Multi-day Transdermal Drug Delivery (MTDD)
Matrix type of design resolves API to form API/Adhesive patch, which is embedded in between Backing Layer and Release Liner. The API containing side of the patch can be adhered to the skin by tearing off the Release Liner. The patch can be designed as double layers for 1-2 days use or single layer for multiple days use.
SB02 is a new drug originated in Taiwan, from discovery, research and development, preclinical ADME.SB02 is an oral active anti-tumor drug NCEProven with multiple anti-cancer MOAReady for IND
PHN015 (Hemorrhage stroke)
Advantages of the productPHN015 is extracted, isolated, and high purified from the Astragalus membranaceus (黃耆) , which has been described in the classical texts as a qi-supplementing Traditional Chinese Medicine(TCM).PHN015 meets the current trend of new drug development ,with bidirectional immunomodulatory functionPHN015 meet the current trend of new drug development ,with two-way immune regulationThere
TLC590 brings sustained release delivery technology to the common anesthetic ropivacaine, with the goal of reducing the frequency of administration for local anesthesia for post-surgical pain. More effective pain relief may also allow patients to avoid the problems of opioid therapies often used for the treatment of post-surgical pain.
PHN013 (Orphan drug;ITP)
Advantages of the productPG2 Injection is originally extracted, isolated and purified from the "superior" Tranditional Chinese Medicine (TCM) and it has been confirmed with high safety because of the over 600 cases clinical practice.PG2 Injection meets the current trend of new drug developmentPG2 Injection synchronously modulates the WBCs, RBCs and Platelets.PG2 Injection has been granted
NanoX™ technology uses nanoparticles coated with the compound polyethylene glycol to reduce uptake by phagocytic cells of the immune system. This prolongs circulation in the body, allowing a drug to predominantly accumulate at particular disease sites such as tumors. Therapies based on NanoX™ technology can also make use of additional molecular coatings to help nanoparticles to accumulate
Advantages of the productAdvantages include replacing complicated surgeries such as harvesting cells from bone marrow .Reducing recovery period for dental implants and alveolar bone reconstruction, and improving patient quality of life.Low immune riskNotable achievementsAwarded Advanced Medical Development and Rapid Commercialization program grant support by the Industrial Development Bureau of the
TLC is using antibodies and antibody fragments attached to lipid encapsulated drugs to develop more effective therapies in oncology. These antibody-linked nanomedicines actively target specific tissues using binding interactions between a specific antibody and a target antigen on the surface of a particular cell type. Compared with passively targeted therapies, these nanomedicines are better able to
AdvantageAdvantages include replacing complicated surgical procedures, such as harvesting cells from cartilage allografting, or bone marrow .Promoting the repair and functional regeneration of cartilage affected by degenerative OA, and improving patients' quality of life.Low immune risk
TLC's BioSeizer™ technology uses multi-layer lipid membranes to encapsulate therapeutically active molecules, providing an exceptionally long duration of drug release. BioSeizer™ nanoparticles are precisely designed to release the payload at a constant rate as each layer collapses over time. In addition, BioSeizer™ technology works to extend the duration of therapies
By encapsulating molecules with poor solubility in polymeric micelle nanoparticles, TLC's technology can increase the solubility of a drug. This allows a larger quantity to be delivered in a single dose, which can enable new forms of administration. For molecules that are too insoluble to be practical as stand-alone therapies, lipid encapsulation may be the key to generating an entirely new type